COGT Cogent Biosciences, Inc. Stock Quote

COGT [NASD]

Index	-	P/E	-	EPS (ttm)	-6.53	Insider Own	4.47%	Shs Outstand	9.85M	Perf Week	-3.28%
Market Cap	473.46M	Forward P/E	-	EPS next Y	-1.27	Insider Trans	0.00%	Shs Float	-	Perf Month	-17.60%
Income	-61.20M	PEG	-	EPS next Q	-0.55	Inst Own	52.90%	Short Float	-	Perf Quarter	-37.76%
Sales	23.20M	P/S	20.41	EPS this Y	24.70%	Inst Trans	256.38%	Short Ratio	3.38	Perf Half Y	-7.87%
Book/sh	-2.25	P/B	-	EPS next Y	68.30%	ROA	-94.40%	Target Price	-	Perf Year	275.68%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-448.70%	52W Range	1.18 - 14.88	Perf YTD	-29.12%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-101.20%	52W High	-46.51%	Beta	-
Dividend %	-	Quick Ratio	6.60	Sales past 5Y	-	Gross Margin	-	52W Low	574.58%	ATR	0.60
Employees	72	Current Ratio	6.60	Sales Q/Q	-70.00%	Oper. Margin	-	RSI (14)	36.13	Volatility	7.63% 6.53%
Optionable	No	Debt/Eq	-	EPS Q/Q	-226.20%	Profit Margin	-	Rel Volume	0.63	Prev Close	7.93
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	449.83K	Price	7.96
Recom	1.20	SMA20	-11.38%	SMA50	-22.91%	SMA200	-14.64%	Volume	286,027	Change	0.38%

Dec-23-20

Initiated

Piper Sandler

Overweight

$22

Oct-14-20

Initiated

Ladenburg Thalmann

Buy

Feb-22-21 07:00AM	Cogent Biosciences Appoints Accomplished Finance Executive Todd E. Shegog to its Board of Directors PR Newswire -5.60%
Feb-18-21 07:00AM	Cogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global Healthcare Conference 2021 PR Newswire
Feb-11-21 07:00AM	Cogent Biosciences to Present at LifeSci Partners Virtual Precision Oncology Day 2021 PR Newswire
Dec-04-20 05:16PM	Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares PR Newswire
Dec-01-20 11:08PM	Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock PR Newswire +6.73%
Nov-30-20 04:01PM	Cogent Biosciences Announces $60.0 Million Public Offering of Shares of Common Stock PR Newswire
07:00AM	Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer PR Newswire
Nov-20-20 07:00AM	Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference PR Newswire
Nov-18-20 09:00AM	Cogent Biosciences Announces Final Results from PLX9486 Phase 1/2 Study in Advanced GIST Patients at CTOS 2020 PR Newswire
Nov-12-20 04:30PM	Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Conference PR Newswire
Nov-09-20 07:00AM	Cogent Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates PR Newswire
Nov-05-20 07:00AM	Cogent Biosciences to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference PR Newswire -5.32%
Oct-26-20 07:00AM	Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officer PR Newswire
Apr-01-20 01:42AM	Edited Transcript of COGT earnings conference call or presentation 12-Mar-20 8:30pm GMT Thomson Reuters StreetEvents -6.36%
Nov-13-19 06:22PM	Edited Transcript of COGT earnings conference call or presentation 11-Nov-19 9:30pm GMT Thomson Reuters StreetEvents

Unum Therapeutics Inc., a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a A'bolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience